What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? A Gynecologic Oncology Group ancillary data study

Gynecologic Oncology ◽

Oncology Group ◽

Ancillary Data ◽

Stage Iiic

What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study

Cancer ◽

10.1002/cncr.30414 ◽

2016 ◽

Vol 123 (6) ◽

pp. 985-993 ◽

Cited By ~ 10

Author(s):

Bunja J. Rungruang ◽

Austin Miller ◽

Thomas C. Krivak ◽

Neil S. Horowitz ◽

Noah Rodriguez ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Oncology Group ◽

Ancillary Data ◽

Stage Iiic

Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218

Gynecologic Oncology ◽

10.1016/j.ygyno.2019.07.020 ◽

2019 ◽

Vol 155 (1) ◽

pp. 69-74 ◽

Cited By ~ 1

Author(s):

K.N. Slaughter Wade ◽

M.F. Brady ◽

T. Thai ◽

Y. Wang ◽

B. Zheng ◽

...

Keyword(s):

Ovarian Cancer ◽

Data Analysis ◽

Gynecologic Oncology ◽

Prognostic Biomarkers ◽

Oncology Group ◽

Ancillary Data

Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study

Gynecologic Oncology ◽

10.1016/j.ygyno.2017.07.121 ◽

2017 ◽

Vol 147 (1) ◽

pp. 98-103 ◽

Cited By ~ 10

Author(s):

N.T. Phippen ◽

A.A. Secord ◽

S. Wolf ◽

G. Samsa ◽

B. Davidson ◽

...

Keyword(s):

Quality Of Life ◽

Ovarian Cancer ◽

Data Analysis ◽

Gynecologic Oncology ◽

Advanced Epithelial Ovarian Cancer

Oncology Group ◽

Ancillary Data ◽

Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study

Gynecologic Oncology ◽

10.1016/j.ygyno.2017.11.018 ◽

2018 ◽

Vol 148 (2) ◽

pp. 275-280 ◽

Cited By ~ 14

Author(s):

C.A. Hamilton ◽

A. Miller ◽

Y. Casablanca ◽

N.S. Horowitz ◽

B. Rungruang ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Advanced Epithelial Ovarian Cancer

Oncology Group ◽

Ancillary Data ◽

Clinicopathologic Characteristics ◽

Term Survival ◽

Maspin expression in epithelial ovarian cancer and associations with poor prognosis: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2006.02.014 ◽

2006 ◽

Vol 101 (3) ◽

pp. 390-397 ◽

Cited By ~ 26

Author(s):

Angeles Alvarez Secord ◽

Paula S. Lee ◽

Kathleen M. Darcy ◽

Laura J. Havrilesky ◽

Lisa A. Grace ◽

...

Keyword(s):

Ovarian Cancer ◽

Poor Prognosis ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Maspin Expression

Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.11.035 ◽

2012 ◽

Vol 124 (3) ◽

pp. 563-568 ◽

Cited By ~ 7

Author(s):

Leslie M. Randall ◽

Michael W. Sill ◽

Robert A. Burger ◽

Bradley J. Monk ◽

Barbara Buening ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Predictive Value ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Ca 125 ◽

Oncology Group ◽

Peritoneal Cancer

Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: A phase I study of the Gynecologic Oncology Group

Gynecologic Oncology ◽

10.1016/j.ygyno.2010.10.018 ◽

2011 ◽

Vol 120 (2) ◽

pp. 224-228 ◽

Cited By ~ 28

Author(s):

Charles A. Kunos ◽

Michael W. Sill ◽

Thomas E. Buekers ◽

Joan L. Walker ◽

Jeanne M. Schilder ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Phase I Study ◽

Low Dose ◽

Gynecologic Oncology ◽

Oncology Group

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.5009 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 5009-5009 ◽

Cited By ~ 36

Author(s):

R. A. Burger ◽

M. Sill ◽

B. J. Monk ◽

B. Greer ◽

J. Sorosky

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Oncology Group ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer

An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2004.05.033 ◽

2004 ◽

Vol 94 (2) ◽

pp. 368-374 ◽

Cited By ~ 40

Author(s):

David H Moore ◽

James T Kauderer ◽

Jeffrey Bell ◽

John P Curtin ◽

Linda Van Le

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Oncology Group ◽

Alternative Treatments ◽

Oncology Group Study ◽

Factors Influencing

Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2012.01.008 ◽

2012 ◽

Vol 125 (2) ◽

pp. 421-426 ◽

Cited By ~ 32

Author(s):

Jennifer M. Rubatt ◽

Kathleen M. Darcy ◽

Chunqiao Tian ◽

Franco Muggia ◽

Rajiv Dhir ◽

...

Keyword(s):

Ovarian Cancer ◽

Clinical Outcomes ◽

Gynecologic Oncology ◽

Advanced Stage ◽

Oncology Group ◽

Oncology Group Study ◽

Pre Treatment ◽

Tumor Expression